07:00 , Apr 14, 2003 |  BioCentury  |  Strategy

M&A adds fuel to the fire

Big Spenders M&A adds fuel to the fire Many biotechs making the shift from toolkit models or early stage research to more fully integrated product development companies are doing so with the help of mergers...
08:00 , Feb 25, 2002 |  BioCentury  |  Strategy

Transition Diary: Deltagen completes Part 1

Deltagen Inc. 's acquisition of Bristol-Myers Squibb Pharma Research Labs L.L.C., formerly CombiChem Inc. , which was completed last week, provides the last big piece DGEN needed to complete the first half of its value-added...
07:00 , Jul 30, 2001 |  BC Week In Review  |  Company News

Arcaris, Deltagen deal

DGEN will acquire functional proteomics company Arcaris for 765,000 DGEN shares valued at $6.7 million based on DGEN's Friday close at $8.70, plus $450,000 in cash. Arcaris shareholders are eligible to receive an additional 550,000...
07:00 , Jul 26, 2001 |  BC Extra  |  Company News

Deltagen to acquire Arcaris

Genomics company DGEN will acquire functional proteomics play Arcaris (Salt Lake City, Utah) for 765,000 DGEN shares, valued at $6.8 million based on DGEN's Wednesday close at $8.84, plus $450,000 in cash. Arcaris shareholders are...
07:00 , Aug 7, 2000 |  BC Week In Review  |  Company News

CuraGen management update

CuraGen Corp. (CRGN), New Haven, Conn.   Business: Drug discovery   Hired: M. Scott Salka as president and CEO of CRGN’s 454 Corp. subsidiary, formerly president and CEO of Arcaris Inc.  ...
07:00 , Aug 1, 2000 |  BC Extra  |  Company News

CuraGen subsidiary names CEO

Drug discovery play CRGN hired M. Scott Salka as president and CEO of its 454 Corp. subsidiary (Branford, Conn.), which is developing genomic and proteomic technologies. Formerly, Salka was president and CEO of Arcaris (Salt...
07:00 , May 30, 2000 |  BC Week In Review  |  Clinical News

Nucleic acid isolation and analysis technology regulatory update

Arcaris received U.S. Patent No. 6,060,240 covering the isolation and evaluation of nucleic acids immobilized on a solid support such as a bead. Arcaris Inc., Salt Lake City, Utah   Product: Nucleic acid isolation and...
07:00 , Apr 24, 2000 |  BC Week In Review  |  Clinical News

Perturbagen peptide libraries regulatory update

Arcaris received U.S. Patent No. 6,025,485 covering its Perturbagen peptide probes displayed on fluorescent protein scaffolds for target identification and validation. Arcaris Inc., Salt Lake City, Utah   Product: Perturbagen peptide libraries   Business: Drug...